COVID-19 is a Real Headache!


Creative Commons License

Bolay H. B., Gül A., Baykal B.

HEADACHE, cilt.60, ss.1415-1421, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1111/head.13856
  • Dergi Adı: HEADACHE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CINAHL, EMBASE, MEDLINE, Public Affairs Index, SportDiscus
  • Sayfa Sayıları: ss.1415-1421
  • Anahtar Kelimeler: coronavirus disease 2019, headache symptoms, headache pathophysiology, angiotensin-converting enzyme 2, vasculopathy, inflammatory mediators, DELETION POLYMORPHISM, MIGRAINE, INFECTION, BRAIN, SUSCEPTIBILITY, SYSTEM, RAT
  • Gazi Üniversitesi Adresli: Evet

Özet

After the emergence of a novel coronavirus named SARS-CoV-2, coronavirus disease 2019 (COVID-19) was initially characterized by fever, sore throat, cough, and dyspnea, mainly manifestations of respiratory system. However, other manifestations such as headache, abdominal pain, diarrhea, loss of taste and smell were added to the clinical spectrum, during the course of the COVID-19 pandemic. The reports on the neurological findings are increasing rapidly and headache seems to be the leader on the symptom list. Headache was reported in 11%-34% of the hospitalized COVID-19 patients, but clinical features of these headaches were totally missing in available publications. According to our initial experience, significant features of headache presentation in the symptomatic COVID-19 patients were new-onset, moderate-severe, bilateral headache with pulsating or pressing quality in the temporoparietal, forehead or periorbital region. The most striking features of the headache were sudden to gradual onset and poor response to common analgesics, or high relapse rate, that was limited to the active phase of the COVID-19. Symptomatic COVID-19 patients, around 6%-10%, also reported headache as a presenting symptom. The possible pathophysiological mechanisms of headache include activation of peripheral trigeminal nerve endings by the SARS-CoV-2 directly or through the vasculopathy and/or increased circulating pro-inflammatory cytokines and hypoxia. We concluded that as a common non-respiratory symptom of COVID-19, headache should not be overlooked, and its characteristics should be recorded with scrutiny.